Previous 10 | Next 10 |
CARSON CITY, Nev., April 18, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, to...
ORLANDO, FL / ACCESSWIRE / April 12, 2024 / RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, April 13, at 7 p.m. Eastern ...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In BioVie To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - March 17, 2024) - Faruqi & Faruqi, LLP, a leading national se...
SAN FRANCISCO, March 15, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now . Class Period: Aug. 5, 2021 – Nov. 29, 2023 Lead Plaintiff Deadline: Mar. 19, 2024 Visit: ww...
Philadelphia, Pennsylvania--(Newsfile Corp. - March 13, 2024) - A securities fraud lawsuit has been filed against BioVie Inc. ("BioVie" or the "Company") (NASDAQ: BIVI). The lawsuit is captioned Olmstead v. BioVie Inc. et al. , No. 3:24-cv-00035 (D. Nev.), and is filed on behalf of purchasers of...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In BioVie To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - March 11, 2024) - Faruqi & Faruqi, LLP, a leading national se...
Recently completed financing provides sufficient funds for near-term Parkinson’s Disease priority Plans for Phase 2b trial of NE3107 as first-line monotherapy for Parkinson’s Disease being finalized with targeted launch late-summer 2024 Once-daily NE3107 formulatio...
CARSON CITY, Nev., March 06, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-dege...
A look at the top 10 most actives in the United States Jaguar Health Inc. (JAGX) rose 61.6% to $0.143 on volume of 387,468,585 shares Fisker Inc. Class A (FSR) fell 8.5% to $0.4415 on volume of 205,557,321 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 3.0% to $3.22 on vol...
A look at the top 10 most actives in the United States Jaguar Health Inc. (JAGX) rose 58.0% to $0.1398 on volume of 323,150,710 shares Fisker Inc. Class A (FSR) fell 6.7% to $0.45 on volume of 175,737,100 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 6.2% to $3.115 on vol...
News, Short Squeeze, Breakout and More Instantly...
BioVie Inc. Company Name:
BIVI Stock Symbol:
OTCMKTS Market:
Jet.AI Inc. (JTAI) is expected to report for Q1 2024 Forian Inc. (FORA) is expected to report $-0.02 for Q1 2024 Square Enix Holdings Co. Ltd (SQNXF) is expected to report for Q4 2024 Qutoutiao Inc. (QTT) is expected to report for Q4 2023 Molecular Partners AG (MOLN) is expected t...
Increasing evidence supports a role for viral persistence, chronic inflammation and immune and metabolic dysregulation in driving long COVID Bezisterim, an anti-inflammatory and insulin-sensitizer that permeates the blood brain barrier, could represent a novel oral treatment targeting a...